Lucerna
Momentum Biotechnologies, founded in 2014, is a drug discovery partner providing specialized mass spectrometry technologies to clients worldwide. Through a diverse array of services, including affinity-selection mass spectrometry (ASMS), covalent binding assays, proteomics / chemoproteomics, and small-molecule analysis, Momentum helps clients identify, validate, and characterize therapeutic leads, accelerating critical drug discovery efforts. In early 2025, Momentum expanded to Europe, where it operates as OmicScouts, a Momentum Biotechnologies Company.
